Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer, Skin and Soft Tissue Infections |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/22/2017 |
| Start Date: | January 2012 |
| End Date: | December 2016 |
Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute S. Aureus Skin and Skin Structure Infections in Patients With Comorbid Conditions: A Randomized Trial
In this pilot study, the objective is to determine the prevalence of asymptomatic carriage of
S. aureus in patients with ABSSSIs and minor cutaneous abscesses after therapy with either
linezolid or clindamycin at 40 days after the completion of therapy. Secondarily, the
investigators will assess the efficacy of linezolid vs. clindamycin in the empiric therapy of
ABSSSIs and minor cutaneous abscesses, as well as the genotypic spectrum of S. aureus
isolates causing ABSSSIs or minor cutaneous abscesses and colonization in the target patient
population before and after therapy. Given the results of a recent study on linezolid and
vancomycin and the investigator's own experience, it is hypothesized that persistent MRSA
carriage will be less common after therapy with linezolid for ABSSSIs and minor cutaneous
abscesses than it is with oral clindamycin.
S. aureus in patients with ABSSSIs and minor cutaneous abscesses after therapy with either
linezolid or clindamycin at 40 days after the completion of therapy. Secondarily, the
investigators will assess the efficacy of linezolid vs. clindamycin in the empiric therapy of
ABSSSIs and minor cutaneous abscesses, as well as the genotypic spectrum of S. aureus
isolates causing ABSSSIs or minor cutaneous abscesses and colonization in the target patient
population before and after therapy. Given the results of a recent study on linezolid and
vancomycin and the investigator's own experience, it is hypothesized that persistent MRSA
carriage will be less common after therapy with linezolid for ABSSSIs and minor cutaneous
abscesses than it is with oral clindamycin.
Inclusion Criteria:
- having an ABSSSI or a minor cutaneous abscess treated in the ED
- age 18 years or older
- any one or more of the following co-morbidities:
- diagnosis of diabetes mellitus
- obesity with a BMI >35
- chronic kidney disease
- coronary artery disease
- peripheral vascular disease
Exclusion Criteria:
- known history of or current thrombocytopenia
- Currently taking anti-depression medication
- Current or recent hospitalization
- Known current alcohol or drug abuse
- Known or suspected hypersensitivity to any ingredient of the study drugs
- Irregular heart rate and blood pressure measurements
- Fevers or low body temperature
- Known psychiatric condition
- Superficial skin infection
- Skin infection caused from an animal bite
- Recent treatment with antibacterials
- Pregnancy
Other protocol related inclusion/exclusion criteria may apply.
We found this trial at
2
sites
5841 S Maryland Ave
Chicago, Illinois 60637
Chicago, Illinois 60637
(773) 702-1000
Principal Investigator: Michael David, MD, PhD
Phone: 773-702-3904
University of Chicago Medical Center The University of Chicago Medicine has been at the forefront...
Click here to add this to my saved trials
80 Jesse Hill Jr Dr SE
Atlanta, Georgia 30303
Atlanta, Georgia 30303
(404) 616-1000
Principal Investigator: Lilly Immergluck, MD, MS
Phone: 404-702-2711
Grady Memorial Hospital Grady is an internationally recognized teaching hospital staffed exclusively by doctors from...
Click here to add this to my saved trials